Loading…
Employees: 920
Size Ningbo David Medical Device (300314.SZ) is a China Health Care company (Medical Specialties) with a market value of $607M, the 3390th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.05 on 6 Nov 2026.
Performance Over six months the shares gained 21.8%, against -14.2% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +9.3%); the operating margin is 11.4% (peer median 7.4%).
Valuation It trades at 12.3× forward earnings against a peer median of 23.9× (2nd cheapest of 11).
Capital Return on invested capital runs 2.6 points above its cost of capital (7.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥613M | CN¥581M | CN¥524M | CN¥613M | CN¥502M |
| Revenue growth | — | +11% | -14% | +22% | — |
| Gross profit | CN¥317M | CN¥298M | CN¥281M | CN¥337M | CN¥278M |
| EBITDA | n/a | CN¥99.6M | CN¥86.5M | CN¥154M | CN¥111M |
| Net income | CN¥92.1M | CN¥87.1M | CN¥57.3M | CN¥148M | CN¥97.4M |
| Free cash flow | -CN¥57.7M | CN¥49.4M | -CN¥38.8M | CN¥112M | CN¥73.2M |
| Capital expenditure | CN¥31.9M | CN¥55.0M | CN¥140M | CN¥40.4M | CN¥49.8M |
| Total debt | CN¥4.60M | CN¥6.01M | CN¥8.82M | CN¥13.7M | CN¥14.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300314.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.5% | -5.1% | 4th highest of 20 |
| 6-month return | +21.8% | -14.2% | 3rd highest of 20 |
| Distance from 52-week high | -16.9% | -36.2% | 4th highest of 20 |
| Revenue growth (TTM) | +18.6% | +9.3% | 3rd highest of 20 |
| Operating margin | 11.4% | 7.4% | 8th highest of 20 |
| Forward P/E | 12.3× | 23.9× | 2nd cheapest of 11 |
| ROIC minus cost of capital | +2.6 pp | -0.7 pp | 6th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ningbo David Medical Device 300314.SZ | China | $607M | +22% | +19% | 11% | 12.3× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $603M | -42% | +28% | 7% | 22.6× | n/a | n/a |
| Medistim MEDI.OL | Norway | $601M | +30% | +19% | 29% | 30.5× | -1.8% | +14.5% |
| Contec Medical Systems 300869.SZ | China | $600M | -23% | -2% | -16% | n/a | 17.3% | -19.8% |
| Nanosonics NAN.AX | Australia | $599M | -13% | +3% | 7% | 90.3× | 34.4% | +6.7% |
| Hangzhou AGS MedTech 688581.SS | China | $617M | -16% | -18% | 33% | 19.8× | 1.7% | +27.8% |
| Tactile Systems Technology TCMD | United States | $583M | +1% | +14% | 9% | 20.8× | 7.8% | +12.0% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $581M | -10% | +6% | 9% | 25.2× | 11.6% | +6.5% |
| Xvivo Perfusion XVIVO.ST | Sweden | $635M | -29% | +18% | 12% | 54.2× | 35.7% | +35.2% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 63.8× | 2.7% | -13.2% |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | n/a | 7.4% | -7.8% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | n/a | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | n/a | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 21.7× | 22.3% | +4.2% |